Koers ESSA Pharma Inc. Toronto S.E.
Aandelen
EPI
CA29668H7085
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 371 mln. 269 mln. 252 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -47 mln. -34,1 mln. -31,98 mln. | Nettowinst (verlies) 2025 * | -72 mln. -52,24 mln. -48,99 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-7,86
x | K/w-verhouding 2025 * |
-5,92
x | Werknemers | 50 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,72% |
Recentste transcriptie over ESSA Pharma Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Parkinson
CEO | Chief Executive Officer | 73 | 24-06-15 |
David Wood
DFI | Director of Finance/CFO | 66 | 01-10-13 |
Peter Virsik
COO | Chief Operating Officer | - | 01-08-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 05-03-15 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 31-07-19 |
Richard Glickman
CHM | Chairman | 65 | 01-10-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. |